All Articles

As R.H. Boyd marks its 130th anniversary, its annual Legacy Ball aims to raise crucial funds, celebrating a history of resilience and investing in future leaders.

After a fatal crash, a private jet operator is publicly demanding regulators and GE fix a critical safety gap where known corrosion goes unreported.

Kevin's Natural Foods enters the breakfast fray with Scramble Starters, a move that's less about eggs and more about a calculated strategy to disrupt the market.

Over $73M in new funding and a $1.8B acquisition signal a seismic shift. As water scarcity meets semiconductor demand, AI is turning water treatment into a high-tech frontier.

A construction firm is merging with an AI robotics leader to go public. The deal, backed by high-profile investors, is built on a new patent that could redefine autonomous warfare and create opportunities far beyond the battlefield.

As new federal work rules loom for Indiana's Medicaid members, MHS is investing millions in a workforce program. Is it a proactive lifeline or a new corporate playbook?

A new tool lets AI agents and developers test an app's hidden plumbing using plain English, signaling a major shift in software quality engineering.

Quoin Pharma's new data for a rare skin disease shows life-changing results in children, offering hope for families. What do the numbers really mean?

In a strategic pivot, GeneDx brings in former Quest and Thermo Fisher exec Mark Gardner to translate its genomic leadership into commercial dominance.

Conifer's oversubscribed fund isn't just about the money. It's a massive wager on a leader's proven playbook for building the core assets of our new economy.

With patient dosing underway for its fibroblast-based DFU therapy, FibroBiologics is testing a new paradigm: healing chronic wounds from within.

As AI-driven attacks escalate, BreachRx adds Phil Venables to its board, signaling a critical shift in how enterprises must manage cyber crises.

A new wave of investment aims to shield America's industrial backbone from cyber threats, bringing modern software discipline to the factory floor.

Eli Lilly's strategic buyout of a Texas biotech isn't just a deal; it's a bet on a new scientific paradigm to solve the chronic pain crisis without opioids.

A small med-tech firm is betting its future on fingerprint sweat. Can its novel drug test pass the FDA's rigorous trials and disrupt a billion-dollar market?

A $25M deal is funding a luxury manufacturer's expansion, revealing a larger story about shifting supply chains and the global appetite for affordable luxury.

With its new stablecoin reserve fund, State Street isn't just launching a product. It's forging a regulated path where traditional finance and digital currency finally meet.

Beyond a simple rebrand, CTM's new integrations and strategic hires reveal a deeper play to solve the market's biggest data disconnect for modern business.

A new partnership highlights how regulatory pressure and data analytics are forcing skilled nursing facilities to adopt tech for safer, more efficient patient care.

California Resources Corporation is swapping old debt for new. We dive into how this $550M move bolsters its balance sheet and fuels its carbon-cutting ambitions.